Local anesthetic improves individuals affected with herpes simplex type 1 labialis

Autor(es)

Bastos, Monica Danielle Ribeiro ^[1] ; de Figueiredo, Fellipe Augusto Tocchini ^[1] ; Macedo, Ana Paula ^[1] ; Silva, Amanda Cristina Funari ^[2] ; Ferreira, Maira Peres ^[2] ; de Freitas, Osvaldo ^[2] ; Pedrazzi, Vinicius ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Dent Mat & Prothesis, Ave Do Cafe S-N, BR-14090504 Ribeirao Preto, SP - Brazil

^[2] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Pharmaceut Sci, Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Medical Virology; v. 92, n. 12 MAY 2020.
• Citações Web of Science: 0

Resumo

Infections caused by the herpes simplex virus 1 (HSV-1), commonly called herpes simplex labialis (HSL), are a public health problem, reaching around 40% of the world's population. Thus, the search for effective therapeutic alternatives in the control of the limitations caused by this virus during the stages of evolution of the disease, is necessary, since they have a direct impact on the quality of life of the patients. The aim of the present study was to evaluate the efficacy of the in situ film precursor semisolid composition in the treatment of herpes simplex lesions in human HSV-1. Ninety-eight (n = 98) patients with HSV-1 were used for this study. The initial exclusion criteria left 81 patients to be considered in the present study. Three applications were performed, the first at time zero (T0) and the other two at 8 and 16 hours, after initial application (T8 and T16). Photographs were taken in the first appointment and 24 and 72 hours after the last application. After the three periods, each patient received a total amount of 90 mg of anesthetic and the prognosis of the patients was followed for 6 months and 1 year after the application. Frequency analysis showed that 40.3% of patients had remission of symptoms 24 hours after the last application. For the present study, the film presented a positive therapeutic potential and an esthetic benefit that is absent in the current products (ointments and gels). The invent presents dosage convenience (only three applications in a 24-hour period) and a low production cost, with a much shorter healing time than that reported using topical antiretrovirals. (AU)

• Processo FAPESP: 12/07251-6 - Desenvolvimento de plataforma com sistemas mucoadesivos para liberação de fármacos na cavidade bucal
• Beneficiário: Osvaldo de Freitas
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 17/24356-0 - Avaliação da eficácia de composição semissólida precursora de filme formado in situ contendo anestésico tópico local para tratamento de pacientes com herpes simplex
• Beneficiário: Natália Cristina Ferreira
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica